- 询价
- WYTSCI
- WT-CB-E20274
- 进口
- 2025年07月12日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
1000+
- 英文名：
3-Acetylamino-3-deoxy-D-glucose
- CAS号：
606-01-9
- 保质期：
咨询
- 供应商：
上海维亦特生物
- 保存条件：
依据标签
| 货号 | 英文名 | CAS | 规格 |
| WT-CB-E20282 | D-Rhamnose | 634-74-2 | 25mg |
| WT-CB-E20246 | D-Ribulose | 488-84-6 | 25mg |
| WT-CB-E20006 | 3-Deoxyoctulosonic acid | 10149-14-1 | 100mg |
| WT-CB-E20329 | L-Fructose | 7776-48-9 | 100mg |
| WT-CB-E20068 | L-Fuculose | 13074-08-3 | 2mg |
| WT-CB-E20147 | L-Psicose | 16354-64-6 | 50mg |
| WT-CB-E20113 | L-Rhamnulose | 14807-05-7 | 10mg |
| WT-CB-E20174 | L-Ribulose | 2042-27-5 | 100mg |
| WT-CB-E20161 | L-Tagatose | 17598-82-2 | 50mg |
| WT-CB-E20255 | L-Xylulose | 527-50-4 | 5mg |
| WT-CB-E20072 | D-Glucal | 13265-84-4 | 10g |
| WT-CB-E20178 | D-Galactal | 21193-75-9 | 10g |
| WT-CB-E20141 | 6-Azido-GlcNAc | 1611491-03-2 | 5mg |
| WT-CB-E20256 | 2-Deoxy-D-xylose | 5284-18-4 | 1g |
| WT-CB-E20274 | 3-Acetylamino-3-deoxy-D-glucose | 606-01-9 | 100mg |
| WT-CB-E20250 | 2,3,4-Tri-O-benzyl-D-glucose | 50272-02-1 | 1g |
| WT-CB-E20241 | 2,6-Dideoxy-D-glucose | 45742-39-0 | 1g |
| WT-CB-E20210 | 3,4,6-Tri-O-acetyl-D-glucal | 2873-29-2 | 1g |
| WT-CB-E20406 | 3-O-Benzyl-2-deoxy-D-arabinopyranose | N/A | 1g |
| WT-CB-E20257 | Methyl-2,3,4-tri-O-benzyl-α-D-glucopyranoside | 53008-65-4 | 1g |
| WT-CB-E20166 | Methyl-2,3,5-tri-O-benzoyl-D-ribofuranoside | 184000-83-7 | 1g |
| WT-CB-E20101 | Methyl-2,3-isopropylidene-α/β-L-rhamnopyranoside | 14133-63-2 | 1g |
| WT-CB-E20380 | Methyl-2-deoxy-α-D-arabinopyranoside | 96038-80-1 | 1g |
| WT-CB-E20102 | Methyl-4,6-O-benzylidene-α-D-glucopyranoside | 14155-23-8 | 1g |
| WT-CB-E20322 | Methyl-D-ribofuranoside | 7473-45-2 | 1g |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验| 货号 | 英文名 | CAS | 规格 |
| WT-CB-E20282 | D-Rhamnose | 634-74-2 | 25mg |
| WT-CB-E20246 | D-Ribulose | 488-84-6 | 25mg |
| WT-CB-E20006 | 3-Deoxyoctulosonic acid | 10149-14-1 | 100mg |
| WT-CB-E20329 | L-Fructose | 7776-48-9 | 100mg |
| WT-CB-E20068 | L-Fuculose | 13074-08-3 | 2mg |
| WT-CB-E20147 | L-Psicose | 16354-64-6 | 50mg |
| WT-CB-E20113 | L-Rhamnulose | 14807-05-7 | 10mg |
| WT-CB-E20174 | L-Ribulose | 2042-27-5 | 100mg |
| WT-CB-E20161 | L-Tagatose | 17598-82-2 | 50mg |
| WT-CB-E20255 | L-Xylulose | 527-50-4 | 5mg |
| WT-CB-E20072 | D-Glucal | 13265-84-4 | 10g |
| WT-CB-E20178 | D-Galactal | 21193-75-9 | 10g |
| WT-CB-E20141 | 6-Azido-GlcNAc | 1611491-03-2 | 5mg |
| WT-CB-E20256 | 2-Deoxy-D-xylose | 5284-18-4 | 1g |
| WT-CB-E20274 | 3-Acetylamino-3-deoxy-D-glucose | 606-01-9 | 100mg |
| WT-CB-E20250 | 2,3,4-Tri-O-benzyl-D-glucose | 50272-02-1 | 1g |
| WT-CB-E20241 | 2,6-Dideoxy-D-glucose | 45742-39-0 | 1g |
| WT-CB-E20210 | 3,4,6-Tri-O-acetyl-D-glucal | 2873-29-2 | 1g |
| WT-CB-E20406 | 3-O-Benzyl-2-deoxy-D-arabinopyranose | N/A | 1g |
| WT-CB-E20257 | Methyl-2,3,4-tri-O-benzyl-α-D-glucopyranoside | 53008-65-4 | 1g |
| WT-CB-E20166 | Methyl-2,3,5-tri-O-benzoyl-D-ribofuranoside | 184000-83-7 | 1g |
| WT-CB-E20101 | Methyl-2,3-isopropylidene-α/β-L-rhamnopyranoside | 14133-63-2 | 1g |
| WT-CB-E20380 | Methyl-2-deoxy-α-D-arabinopyranoside | 96038-80-1 | 1g |
| WT-CB-E20102 | Methyl-4,6-O-benzylidene-α-D-glucopyranoside | 14155-23-8 | 1g |
| WT-CB-E20322 | Methyl-D-ribofuranoside | 7473-45-2 | 1g |
Measurement of Cell Membrane Toxicity by Means of 2-Deoxy-D-Glucose
The membrane theory of toxicity (1 ) emanates from the fact that the plasma membrane is the first barrier met by a toxic agent on reaching the cell, and was first advanced to explain the toxic effects of heavy metals. The vital regulatory
The TALLYHO Mouse as a Model of Human Type 2 Diabetes
, and hyperlipidemia. Glucose intolerance and hyperglycemia are exhibited only in males. Reduced 2-deoxy-glucose uptake occurs in adipose tissue and skeletal muscle of male TH mice. While both sexes of TH mice exhibit enlarged pancreatic islets, only males
The Clinical Use of PET/CT in the Evaluation of Melanoma
-2-(18 F)fluoro-d -glucose (18 F-FDG) as the radiopharmaceutical, PET/CT has demonstrated its efficacy and its utility in the management of patients with advanced melanoma. Nonetheless, challenges remain in the early stage evaluation of melanoma
技术资料暂无技术资料 索取技术资料
